Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 6/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 5/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.36 |
| ▸ | GBA1 | P04062 | 5/20 | 0.34 |
| ▸ | GBA2 | Q9HCG7 | 9/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22515330 | 0.78 | — | — | |
| SCHEMBL3112405 | 0.76 | GNAO1 (0.37) | GNAO1GNAI3GNAI1GBA1GBA2 | |
| SCHEMBL27640022 | 0.76 | GBA1 (0.44) | GBA1GBA2GAA | |
| SCHEMBL3094129 | 0.75 | GNAO1 (0.39) | GNAO1GNAI3GNAI1GBA1GBA2 | |
| Methane SCHEMBL4263062 | 0.74 | GNAO1 (0.38) | GNAO1GNAI3GNAI1GBA1GBA2 | |
| SCHEMBL11707548 | 0.73 | GNAO1 (0.35) | GNAO1GNAI3GNAI1GBA1 | |
| SCHEMBL11707879 | 0.73 | GNAO1 (0.35) | GNAO1GNAI3GNAI1GBA1 | |
| SCHEMBL11709547 | 0.73 | GNAO1 (0.35) | GNAO1GNAI3GNAI1GBA1 | |
| SCHEMBL1140659 | 0.73 | GNAO1 (0.38) | GNAO1GNAI3GNAI1GBA1GBA2 | |
| SCHEMBL11705178 | 0.71 | GNAO1 (0.33) | GNAO1GNAI3GNAI1GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161848-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161848-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | GNAO1 3077/4885GNAI3 1760/4885GNAI1 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.